Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus

Background and Aims Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated t...

Full description

Saved in:
Bibliographic Details
Published inLiver international Vol. 39; no. 5; pp. 967 - 975
Main Authors Hegade, Vinod S., Pechlivanis, Alexandros, McDonald, Julie A. K., Rees, Douglas, Corrigan, Margaret, Hirschfield, Gideon M., Taylor‐Robinson, Simon D., Holmes, Elaine, Marchesi, Julian R., Kendrick, Stuart, Jones, David E.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.05.2019
Subjects
Online AccessGet full text
ISSN1478-3223
1478-3231
1478-3231
DOI10.1111/liv.14069

Cover

Abstract Background and Aims Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor. Methods We studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC‐MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing. Results In PBC patients with pruritus, serum levels of total and glyco‐conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro‐ and glyco‐conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro‐ and glyco‐ conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04). Conclusions Pruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition.
AbstractList Background and AimsPruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor.MethodsWe studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC‐MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing.ResultsIn PBC patients with pruritus, serum levels of total and glyco‐conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro‐ and glyco‐conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro‐ and glyco‐ conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04).ConclusionsPruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition.
Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor. We studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC-MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing. In PBC patients with pruritus, serum levels of total and glyco-conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro- and glyco-conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro- and glyco- conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04). Pruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition.
Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor.BACKGROUND AND AIMSPruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor.We studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC-MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing.METHODSWe studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC-MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing.In PBC patients with pruritus, serum levels of total and glyco-conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro- and glyco-conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro- and glyco- conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04).RESULTSIn PBC patients with pruritus, serum levels of total and glyco-conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro- and glyco-conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro- and glyco- conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04).Pruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition.CONCLUSIONSPruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition.
Background and Aims Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor. Methods We studied fasting serum bile acids (BAs), autotaxin and faecal microbiota in 22 PBC patients with pruritus at baseline and after 2 weeks of GSK2330672 treatment. Control group included 31 asymptomatic PBC patients and 18 healthy volunteers. BA profiling was done by ultra performance liquid chromatography coupled to a mass spectrometry (UPLC‐MS). Faecal microbiomes were analysed by 16S ribosomal RNA gene sequencing. Results In PBC patients with pruritus, serum levels of total and glyco‐conjugated primary BAs and autotaxin were significantly elevated. Autotaxin activity correlated significantly with tauro‐ and glyco‐conjugated cholic acid (CA) and chenodeoxycholic acid (CDCA), both at baseline and after GSK2330672. GSK2330672 significantly reduced autotaxin and all tauro‐ and glyco‐ conjugated BAs and increased faecal levels of CA (P = 0.048) and CDCA (P = 0.027). Gut microbiota of PBC patients with pruritus was similar to control groups. GSK2330672 increased the relative abundance of Firmicutes (P = 0.033) and Clostridia (P = 0.04) and decreased Bacteroidetes (P = 0.033) and Bacteroidia (P = 0.04). Conclusions Pruritus in PBC does not show a distinct gut bacterial profile but is associated with elevated serum bile acid and autotaxin levels which decrease after IBAT inhibition. In cholestatic pruritus, a complex interplay between BAs and autotaxin is likely and may be modified by IBAT inhibition.
Author Hegade, Vinod S.
Jones, David E.
Pechlivanis, Alexandros
Holmes, Elaine
McDonald, Julie A. K.
Kendrick, Stuart
Taylor‐Robinson, Simon D.
Hirschfield, Gideon M.
Corrigan, Margaret
Rees, Douglas
Marchesi, Julian R.
Author_xml – sequence: 1
  givenname: Vinod S.
  orcidid: 0000-0001-9572-2361
  surname: Hegade
  fullname: Hegade, Vinod S.
  email: vinod.hegade@newcastle.ac.uk
  organization: Institute of Cellular Medicine and NIHR Newcastle Biomedical Research Centre, Newcastle University
– sequence: 2
  givenname: Alexandros
  surname: Pechlivanis
  fullname: Pechlivanis, Alexandros
  organization: Imperial College London
– sequence: 3
  givenname: Julie A. K.
  surname: McDonald
  fullname: McDonald, Julie A. K.
  organization: Imperial College London
– sequence: 4
  givenname: Douglas
  surname: Rees
  fullname: Rees, Douglas
  organization: Imperial College London
– sequence: 5
  givenname: Margaret
  surname: Corrigan
  fullname: Corrigan, Margaret
  organization: University of Birmingham
– sequence: 6
  givenname: Gideon M.
  surname: Hirschfield
  fullname: Hirschfield, Gideon M.
  organization: University of Birmingham
– sequence: 7
  givenname: Simon D.
  surname: Taylor‐Robinson
  fullname: Taylor‐Robinson, Simon D.
  organization: Imperial College London
– sequence: 8
  givenname: Elaine
  surname: Holmes
  fullname: Holmes, Elaine
  organization: Imperial College London
– sequence: 9
  givenname: Julian R.
  surname: Marchesi
  fullname: Marchesi, Julian R.
  organization: Cardiff University
– sequence: 10
  givenname: Stuart
  surname: Kendrick
  fullname: Kendrick, Stuart
  organization: GlaxoSmithKline (GSK), Research and Development
– sequence: 11
  givenname: David E.
  surname: Jones
  fullname: Jones, David E.
  organization: Institute of Cellular Medicine and NIHR Newcastle Biomedical Research Centre, Newcastle University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30735608$$D View this record in MEDLINE/PubMed
BookMark eNp9kV1LBCEUhiWKvi_6AyF0U9CWOq7OXEb0BQvdRLeijrbGrG7q9PEL-ts57RYRlDfnqM97OOe8W2DVB28A2MPoBJdz2rnnE0wRa1bAJqa8HlWkwqvfOak2wFZKjwjhphnjdbBRIV6NGao3wftZn0OWr84fQ-U6A6V2LZzHYD8vvoXGWqMzDBaWF9n9oHKUPs1DzCZC56dOueyCL2nRu5mMbwPrhqinoZP-ofwnOJfZGZ8TfHF5Wsg-utynHbBmZZfM7jJug7vLi7vz69Hk9urm_Gwy0lVdNyNMMbVMaooJZUpZwxU1VilKjeZGEU04aVqruawZ4S1BNcFjzqi0miGqq21wuChbJnzqTcpi5pI2XenOhD4JgmuGKavHpKAHv9DH0EdfmhOE4IrTASrU_pLq1cy0Yjm5-NpwAY4WgI4hpWjsN4KRGNwTxT3x6V5hT3-x2mU5LLWs2nX_KV6KK29_lxaTm_uF4gOUa60F
CitedBy_id crossref_primary_10_3389_fmed_2021_639674
crossref_primary_10_3390_nu13031018
crossref_primary_10_1007_s11901_020_00517_x
crossref_primary_10_26416_Aler_8_3_2024_10138
crossref_primary_10_1016_j_gastre_2020_08_002
crossref_primary_10_1016_j_biopha_2020_110835
crossref_primary_10_1007_s40257_022_00710_2
crossref_primary_10_1111_eci_13714
crossref_primary_10_17816_dv635963
crossref_primary_10_3390_ijms26051883
crossref_primary_10_1016_j_bbadis_2020_165958
crossref_primary_10_1016_j_cld_2022_06_003
crossref_primary_10_1016_j_jacbts_2020_10_001
crossref_primary_10_1097_HEP_0000000000000728
crossref_primary_10_1016_j_cgh_2022_10_032
crossref_primary_10_1055_s_0044_1787705
crossref_primary_10_1016_j_jhep_2021_08_025
crossref_primary_10_1007_s11894_019_0713_6
crossref_primary_10_7861_clinmed_2021_0725
crossref_primary_10_1016_S2352_4642_23_00259_6
crossref_primary_10_1080_13543784_2024_2343789
crossref_primary_10_1124_dmd_121_000595
crossref_primary_10_1111_liv_14553
crossref_primary_10_3390_gastroent15020030
crossref_primary_10_1016_j_cld_2022_06_009
crossref_primary_10_1111_liv_15982
crossref_primary_10_1016_j_cca_2024_120004
crossref_primary_10_1111_liv_15030
crossref_primary_10_1016_j_gastrohep_2020_08_001
crossref_primary_10_3390_ijms25084321
Cites_doi 10.1038/nrgastro.2015.46
10.1136/gut.2005.065862
10.1016/j.cbi.2015.08.016
10.1002/hep4.1209
10.1038/msb.2008.56
10.1016/j.autrev.2016.03.019
10.1016/j.dld.2011.10.025
10.1038/s41598-018-25214-0
10.1016/j.jhep.2017.03.022
10.1111/apt.13794
10.3892/ijmm.2015.2233
10.1002/hep.25748
10.1021/acs.analchem.5b01556
10.1111/liv.12680
10.1053/j.gastro.2010.05.009
10.1097/MOG.0000000000000057
10.1073/pnas.1006734107
10.1111/j.1365-2133.2009.09586.x
10.1016/S0168-8278(16)00146-X
10.1016/j.clinbiochem.2006.10.009
10.1038/ncomms11248
10.1053/j.gastro.2011.07.046
10.1136/gutjnl-2015-309618
10.1016/j.cgh.2018.12.007
10.1001/archinte.1972.03650040156014
10.1159/000450988
10.1371/journal.pone.0178580
10.1111/1462-2920.13401
10.1016/S0140-6736(17)30319-7
10.1016/j.autrev.2017.07.002
10.1002/hep.27973
10.1038/nrgastro.2015.114
10.1093/ajcn/27.11.1341
10.1136/gut.12.2.145
10.1016/j.jhep.2015.10.024
10.1136/gutjnl-2016-313332
10.1186/s12876-016-0481-9
10.1016/S0168-8278(16)00697-8
10.1111/j.1572-0241.2007.01200.x
ContentType Journal Article
Copyright 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
2019 John Wiley & Sons A/S
Copyright_xml – notice: 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
– notice: 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
– notice: 2019 John Wiley & Sons A/S
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7T5
7U9
8FD
FR3
H94
K9.
P64
RC3
7X8
DOI 10.1111/liv.14069
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Biotechnology Research Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Virology and AIDS Abstracts
Biotechnology Research Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList Genetics Abstracts
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1478-3231
EndPage 975
ExternalDocumentID 30735608
10_1111_liv_14069
LIV14069
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: GlaxoSmithKline (GSK)
– fundername: National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre
– fundername: Medical Research Council
  grantid: MR/L001489/1
GroupedDBID ---
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
29L
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHQN
AAIPD
AAKAS
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCZN
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFEBI
AFFPM
AFGKR
AFRAH
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AIACR
AIDQK
AIDYY
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
R.K
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
X7M
XG1
ZXP
ZZTAW
~IA
~WT
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7T5
7U9
8FD
FR3
H94
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c3889-1414f6ac41246bbfe7b4efbb44ec7eb2c2729dfc7a8627d208215764afc604c3
IEDL.DBID DR2
ISSN 1478-3223
1478-3231
IngestDate Fri Sep 05 06:07:10 EDT 2025
Wed Aug 13 07:41:51 EDT 2025
Mon Jul 21 06:02:47 EDT 2025
Wed Oct 01 04:49:30 EDT 2025
Thu Apr 24 22:53:08 EDT 2025
Sun Sep 21 06:17:43 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords PBC
microbiota
pruritus
metabonome
Language English
License 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3889-1414f6ac41246bbfe7b4efbb44ec7eb2c2729dfc7a8627d208215764afc604c3
Notes Funding information
This study was funded via the research grant from the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre. BAT117213 sample collection was funded by GlaxoSmithKline (GSK). This paper presents independent research and the views expressed are those of the authors and not necessarily those of the NIHR or GSK.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-9572-2361
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/liv.14069
PMID 30735608
PQID 2213748523
PQPubID 2045125
PageCount 9
ParticipantIDs proquest_miscellaneous_2186146852
proquest_journals_2213748523
pubmed_primary_30735608
crossref_primary_10_1111_liv_14069
crossref_citationtrail_10_1111_liv_14069
wiley_primary_10_1111_liv_14069_LIV14069
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate May 2019
2019-05-00
20190501
PublicationDateYYYYMMDD 2019-05-01
PublicationDate_xml – month: 05
  year: 2019
  text: May 2019
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle Liver international
PublicationTitleAlternate Liver Int
PublicationYear 2019
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2015; 35
2015; 12
2015; 36
2007; 102
2017; 67
1972; 130
2010; 162
2008; 4
2016; 18
2018; 67
2012; 56
2016; 16
2016; 15
2014; 60
1974; 27
2018; 8
2016; 7
2018; 2
2011; 108
2010; 139
2017; 16
1971; 12
2017; 35
1984; 6
2015; 87
2017; 12
2016; 65
2016; 64
2016; 255
2018
2016; 63
2005; 54
2007; 40
2011; 141
2014; 30
2017; 389
2012; 44
2016; 44
e_1_2_9_30_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_10_1
e_1_2_9_35_1
e_1_2_9_13_1
Pares A (e_1_2_9_18_1) 2014; 60
e_1_2_9_32_1
e_1_2_9_12_1
e_1_2_9_33_1
e_1_2_9_15_1
e_1_2_9_38_1
e_1_2_9_14_1
e_1_2_9_39_1
e_1_2_9_17_1
e_1_2_9_36_1
e_1_2_9_16_1
e_1_2_9_37_1
e_1_2_9_41_1
e_1_2_9_42_1
e_1_2_9_20_1
e_1_2_9_40_1
e_1_2_9_22_1
e_1_2_9_21_1
e_1_2_9_24_1
e_1_2_9_23_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_4_1
e_1_2_9_3_1
e_1_2_9_2_1
Padova C (e_1_2_9_31_1) 1984; 6
Herndon JH (e_1_2_9_5_1) 1972; 130
e_1_2_9_9_1
e_1_2_9_26_1
e_1_2_9_25_1
e_1_2_9_28_1
e_1_2_9_27_1
Reig A (e_1_2_9_19_1) 2016; 64
e_1_2_9_29_1
References_xml – volume: 6
  start-page: 773
  issue: 12
  year: 1984
  end-page: 776
  article-title: Double‐blind placebo‐controlled clinical trial of microporous cholestyramine in the treatment of intra‐ and extra‐hepatic cholestasis: relationship between itching and serum bile acids
  publication-title: Methods Find Exp Clin Pharmacol
– volume: 102
  start-page: 1528
  issue: 7
  year: 2007
  end-page: 1536
  article-title: The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis‐associated pruritus
  publication-title: Am J Gastroenterol
– volume: 67
  start-page: 145
  year: 2017
  end-page: 172
  article-title: EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis
  publication-title: J Hepatol
– volume: 44
  start-page: 303
  issue: 4
  year: 2012
  end-page: 310
  article-title: Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study
  publication-title: Dig Liver Dis
– volume: 12
  start-page: e0178580
  issue: 6
  year: 2017
  article-title: Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis
  publication-title: PLoS ONE
– volume: 65
  start-page: 57
  issue: 1
  year: 2016
  end-page: 62
  article-title: Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates
  publication-title: Gut
– volume: 35
  start-page: 267
  issue: 3
  year: 2017
  end-page: 274
  article-title: Apical sodium‐dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis
  publication-title: Digestive diseases (Basel, Switzerland)
– volume: 87
  start-page: 9662
  issue: 19
  year: 2015
  end-page: 9670
  article-title: Bile acid profiling and quantification in biofluids using ultra‐performance liquid chromatography tandem mass spectrometry
  publication-title: Anal Chem
– year: 2018
  article-title: Pruritus is common and under-treated in patients with primary biliary cholangitis in the United Kingdom
  publication-title: Clin Gastroenterol Hepatol
– volume: 2
  start-page: 1037
  issue: 9
  year: 2018
  end-page: 1050
  article-title: NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double‐blind, placebo‐controlled trial
  publication-title: Hepatol Commun
– volume: 130
  start-page: 632
  issue: 4
  year: 1972
  end-page: 637
  article-title: Pathophysiology of pruritus associated with elevated bile acid levels in serum
  publication-title: Arch Intern Med
– volume: 40
  start-page: 274
  issue: 3–4
  year: 2007
  end-page: 277
  article-title: Measurement of lysophospholipase D/autotaxin activity in human serum samples
  publication-title: Clin Biochem
– volume: 60
  start-page: 358A
  year: 2014
  article-title: Circulating bile acids and sterol levels in patients with cholestatic pruritus. Effects of albumin dialysis using Mars: 313
  publication-title: Hepatology
– volume: 12
  start-page: 253
  issue: 5
  year: 2015
  end-page: 254
  article-title: Gut microbiota: Optimal sampling of the intestinal microbiota for research
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 12
  start-page: 145
  issue: 2
  year: 1971
  end-page: 152
  article-title: Serum bile acids in liver disease
  publication-title: Gut
– volume: 12
  start-page: 458
  issue: 8
  year: 2015
  end-page: 471
  article-title: The promise of metabolic phenotyping in gastroenterology and hepatology
  publication-title: Nat Rev Gastroenterol Hepatol
– volume: 36
  start-page: 377
  issue: 2
  year: 2015
  end-page: 385
  article-title: Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis
  publication-title: Int J Mol Med
– volume: 141
  start-page: 1773
  issue: 5
  year: 2011
  end-page: 1781
  article-title: Bile acid is a host factor that regulates the composition of the cecal microbiota in rats
  publication-title: Gastroenterology
– volume: 64
  start-page: S197
  issue: 2
  year: 2016
  article-title: Clarity: a phase 2, randomized, double‐blind, placebo‐controlled study of lopixibat chloride (Formerly Lum001), a novel apical sodium‐dependent bile acid transporter inhibitor, in the treatment of primary biliary cirrhosis associated with itching
  publication-title: J Hepatol
– volume: 64
  start-page: S429
  issue: 2
  year: 2016
  article-title: Bezafibrate alleviates pruritus and decreases specific circulating metabolites in patients with primary biliary cholangitis
  publication-title: J Hepatol
– volume: 162
  start-page: 587
  issue: 3
  year: 2010
  end-page: 593
  article-title: The 5‐D itch scale: a new measure of pruritus
  publication-title: Br J Dermatol
– volume: 18
  start-page: 2272
  issue: 7
  year: 2016
  end-page: 2286
  article-title: Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis
  publication-title: Environ Microbiol
– volume: 139
  start-page: 1008
  issue: 3
  year: 2010
  end-page: 1018
  article-title: Lysophosphatidic acid is a potential mediator of cholestatic pruritus
  publication-title: Gastroenterology
– volume: 56
  start-page: 1391
  issue: 4
  year: 2012
  end-page: 1400
  article-title: Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions
  publication-title: Hepatology
– volume: 8
  start-page: 6658
  issue: 1
  year: 2018
  article-title: Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis
  publication-title: Sci Rep
– volume: 16
  start-page: 885
  issue: 9
  year: 2017
  end-page: 896
  article-title: Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases
  publication-title: Autoimmun Rev
– volume: 255
  start-page: 83
  year: 2016
  end-page: 91
  article-title: Oxidative stress markers, secondary bile acids and sulfated bile acids classify the clinical liver injury type: Promising diagnostic biomarkers for cholestasis
  publication-title: Chem Biol Interact
– volume: 44
  start-page: 1039
  issue: 10
  year: 2016
  end-page: 1050
  article-title: The inter‐relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis
  publication-title: Aliment Pharmacol Ther
– volume: 27
  start-page: 1341
  issue: 11
  year: 1974
  end-page: 1347
  article-title: Microbial bile acid transformation
  publication-title: Am J Clin Nutr
– volume: 54
  start-page: 1622
  issue: 11
  year: 2005
  end-page: 1629
  article-title: Development, validation, and evaluation of the PBC‐40, a disease specific health related quality of life measure for primary biliary cirrhosis
  publication-title: Gut
– volume: 67
  start-page: 534
  issue: 3
  year: 2018
  end-page: 541
  article-title: Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy
  publication-title: Gut
– volume: 7
  start-page: 11248
  year: 2016
  article-title: Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling
  publication-title: Nat Commun
– volume: 30
  start-page: 332
  issue: 3
  year: 2014
  end-page: 338
  article-title: Bile acids and the gut microbiome
  publication-title: Curr Opin Gastroenterol
– volume: 389
  start-page: 1114
  issue: 10074
  year: 2017
  end-page: 1123
  article-title: Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double‐blind, randomised, placebo‐controlled, crossover, phase 2a study
  publication-title: Lancet
– volume: 4
  start-page: 219
  year: 2008
  article-title: Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes
  publication-title: Mol Syst Biol
– volume: 35
  start-page: 263
  issue: 1
  year: 2015
  end-page: 274
  article-title: Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis
  publication-title: Liver Int
– volume: 108
  start-page: 4523
  issue: Suppl 1
  year: 2011
  end-page: 4530
  article-title: Systemic gut microbial modulation of bile acid metabolism in host tissue compartments
  publication-title: Proc Natl Acad Sci U S A
– volume: 63
  start-page: 512
  issue: 2
  year: 2016
  end-page: 523
  article-title: Pharmacological inhibition of apical sodium‐dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice
  publication-title: Hepatology
– volume: 16
  start-page: 71
  issue: 1
  year: 2016
  article-title: BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial
  publication-title: BMC Gastroenterol
– volume: 64
  start-page: 674
  issue: 3
  year: 2016
  end-page: 681
  article-title: Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis
  publication-title: J Hepatol
– volume: 15
  start-page: 795
  issue: 8
  year: 2016
  end-page: 800
  article-title: Autotaxin, pruritus and primary biliary cholangitis (PBC)
  publication-title: Autoimmun Rev
– ident: e_1_2_9_41_1
  doi: 10.1038/nrgastro.2015.46
– ident: e_1_2_9_25_1
  doi: 10.1136/gut.2005.065862
– ident: e_1_2_9_17_1
  doi: 10.1016/j.cbi.2015.08.016
– ident: e_1_2_9_28_1
  doi: 10.1002/hep4.1209
– ident: e_1_2_9_37_1
  doi: 10.1038/msb.2008.56
– ident: e_1_2_9_6_1
  doi: 10.1016/j.autrev.2016.03.019
– ident: e_1_2_9_14_1
  doi: 10.1016/j.dld.2011.10.025
– ident: e_1_2_9_10_1
  doi: 10.1038/s41598-018-25214-0
– ident: e_1_2_9_2_1
  doi: 10.1016/j.jhep.2017.03.022
– ident: e_1_2_9_4_1
  doi: 10.1111/apt.13794
– ident: e_1_2_9_16_1
  doi: 10.3892/ijmm.2015.2233
– ident: e_1_2_9_7_1
  doi: 10.1002/hep.25748
– ident: e_1_2_9_26_1
  doi: 10.1021/acs.analchem.5b01556
– ident: e_1_2_9_15_1
  doi: 10.1111/liv.12680
– ident: e_1_2_9_33_1
  doi: 10.1053/j.gastro.2010.05.009
– ident: e_1_2_9_35_1
  doi: 10.1097/MOG.0000000000000057
– ident: e_1_2_9_38_1
  doi: 10.1073/pnas.1006734107
– volume: 60
  start-page: 358A
  year: 2014
  ident: e_1_2_9_18_1
  article-title: Circulating bile acids and sterol levels in patients with cholestatic pruritus. Effects of albumin dialysis using Mars: 313
  publication-title: Hepatology
– ident: e_1_2_9_24_1
  doi: 10.1111/j.1365-2133.2009.09586.x
– ident: e_1_2_9_9_1
  doi: 10.1016/S0168-8278(16)00146-X
– ident: e_1_2_9_27_1
  doi: 10.1016/j.clinbiochem.2006.10.009
– ident: e_1_2_9_34_1
  doi: 10.1038/ncomms11248
– ident: e_1_2_9_22_1
  doi: 10.1053/j.gastro.2011.07.046
– volume: 6
  start-page: 773
  issue: 12
  year: 1984
  ident: e_1_2_9_31_1
  article-title: Double‐blind placebo‐controlled clinical trial of microporous cholestyramine in the treatment of intra‐ and extra‐hepatic cholestasis: relationship between itching and serum bile acids
  publication-title: Methods Find Exp Clin Pharmacol
– ident: e_1_2_9_42_1
  doi: 10.1136/gutjnl-2015-309618
– ident: e_1_2_9_3_1
  doi: 10.1016/j.cgh.2018.12.007
– volume: 130
  start-page: 632
  issue: 4
  year: 1972
  ident: e_1_2_9_5_1
  article-title: Pathophysiology of pruritus associated with elevated bile acid levels in serum
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.1972.03650040156014
– ident: e_1_2_9_11_1
  doi: 10.1159/000450988
– ident: e_1_2_9_29_1
  doi: 10.1371/journal.pone.0178580
– ident: e_1_2_9_20_1
  doi: 10.1111/1462-2920.13401
– ident: e_1_2_9_12_1
  doi: 10.1016/S0140-6736(17)30319-7
– ident: e_1_2_9_36_1
  doi: 10.1016/j.autrev.2017.07.002
– ident: e_1_2_9_39_1
  doi: 10.1002/hep.27973
– ident: e_1_2_9_13_1
  doi: 10.1038/nrgastro.2015.114
– ident: e_1_2_9_23_1
  doi: 10.1093/ajcn/27.11.1341
– ident: e_1_2_9_30_1
  doi: 10.1136/gut.12.2.145
– ident: e_1_2_9_40_1
  doi: 10.1016/j.jhep.2015.10.024
– ident: e_1_2_9_21_1
  doi: 10.1136/gutjnl-2016-313332
– ident: e_1_2_9_8_1
  doi: 10.1186/s12876-016-0481-9
– volume: 64
  start-page: S429
  issue: 2
  year: 2016
  ident: e_1_2_9_19_1
  article-title: Bezafibrate alleviates pruritus and decreases specific circulating metabolites in patients with primary biliary cholangitis
  publication-title: J Hepatol
  doi: 10.1016/S0168-8278(16)00697-8
– ident: e_1_2_9_32_1
  doi: 10.1111/j.1572-0241.2007.01200.x
SSID ssj0019951
Score 2.4197276
Snippet Background and Aims Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is...
Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a...
Background and AimsPruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 967
SubjectTerms Acids
Adult
Aged
Bile
Bile acids
Bile Acids and Salts - blood
Biomarkers - blood
Carrier Proteins
Case-Control Studies
Chenodeoxycholic acid
Chenodeoxycholic Acid - pharmacology
Cholangitis
Cholic acid
Cholic Acid - pharmacology
Chromatography, Liquid
Feces - chemistry
Feces - microbiology
Female
Gene sequencing
Humans
Inhibition
Intestinal microflora
Liquid chromatography
Liver Cirrhosis, Biliary - complications
Male
Mass spectrometry
Mass spectroscopy
Membrane Glycoproteins
metabonome
Methylamines - pharmacology
Microbiomes
Microbiota
Middle Aged
PBC
Phosphoric Diester Hydrolases - blood
Pruritus
Pruritus - blood
Pruritus - drug therapy
Pruritus - etiology
Relative abundance
Ribonucleic acid
RNA
RNA, Ribosomal, 16S - genetics
rRNA 16S
Serum levels
Tandem Mass Spectrometry
Thiazepines - pharmacology
Title Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fliv.14069
https://www.ncbi.nlm.nih.gov/pubmed/30735608
https://www.proquest.com/docview/2213748523
https://www.proquest.com/docview/2186146852
Volume 39
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1478-3231
  dateEnd: 20241001
  omitProxy: true
  ssIdentifier: ssj0019951
  issn: 1478-3223
  databaseCode: ABDBF
  dateStart: 20030201
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVWIB
  databaseName: Wiley Online Library - Core collection (SURFmarket)
  issn: 1478-3223
  databaseCode: DR2
  dateStart: 19970101
  customDbUrl:
  isFulltext: true
  eissn: 1478-3231
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0019951
  providerName: Wiley-Blackwell
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT9VAEJ4QTIwvoqByEMlCjPGBQ3rZbnvi00E8QQM8ECQ8mDS7293QAD0JbYn6B_zbzmy3FbwkxKdu2ml2285059uZ_QbgdRboIjaIThIpxZhrbBEnCOpyNsl0FGjuwgWHR2L_M_90lpwtwLt-L0zHDzEsuJFluP81GbhU9S0jvyxv0MwDQZv3wjhxIdrjgTqKdh47sMUp_I9zoGcVoiye4c67c9EfDuZdf9VNOLMl-NIPtcszudhpG7Wjv__G4vifz_IEHntHlE07zXkKC6ZahpVphSD86ht7w1xqqFtzX4aHhz4CvwI_pm0zb-TXstpmCvtiUpcF85W_mawK1mWIsLlleAZ7-CXVDETq16yszkvl0sWwifc7zguSLenoEDdVUipr5plfa0ZLxihJ5fba-hmczD6cvN8f-2IOYx1TJlXIQ26F1FTtWihlTaq4sUpxbnSK8F5H6OYXVqcSMVZaROiahIiFuLRaBFzHz2GxmldmFZhVRmRpzHVgQq6KYBJrHhRWWSkSGwfRCN72XzXXnuic6m1c5j3gwdedu9c9gq1B1D_p34TWe9XIvYHXeRSFRNyDMH4Em8NlNE2Kt8jKzFuUCTNBO9sSHNKLTqWGXujXis5mhoN1ivHv7vODj6eusXZ_0ZfwCB27SZeYuQ6LzXVrXqHz1KgNeDDd3dudbThr-QlPTxiT
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NIcFeBqwwCgMMQogHOuXDdVJpLxVQFWj7gAraC4psx9aijVRakwn4B_Zv785xMsaHhHiKk1xkO7mL72effwfwPA10HhtEJ0MpxYBrLBEnCOpyOkp1FGjulgvmCzH9xN8fDg834KDdC9PwQ3QTbmQZ7n9NBk4T0j9Z-UlxhnYeiNE1uE7rc2SWbz525FG099jBLU4BADgKel4hiuPpHr06Gv3mYl71WN2QM7kFX9rGNpEmx_t1pfb1j194HP-3N7dh2_uibNwozx3YMOUO9MYl4vCv39kL5qJD3bT7DtyY-0X4HpyP62pVyW9F-YoprIxJXeTMJ_9mssxZEyTCVpbhFazhUqrquNRPWVEeFcpFjGERn3e0FyRb0NGBbkqmVKyZJ39dM5o1RknKuFev78Jy8nb5ejrw-RwGOqZgqpCH3AqpKeG1UMqaRHFjleLc6AQRvo7Q08-tTiTCrCSP0DsJEQ5xabUIuI7vwWa5Ks19YFYZkSYx14EJucqDUax5kFtlpRjaOIj68LL9rJn2XOeUcuMkazEPvu7Mve4-POtEfU__JLTX6kbmbXydRVFI3D2I5PvwtLuN1klLLrI0qxplwlTQ5rYhNmm30amuFvq7or-ZYmOdZvy9-mz27rMrPPh30Sdwc7qcz_B88eEhbKGfN2riNPdgszqtzSP0pSr12JnMBecfGz0
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9UwFD8BTIgvqIB4FbQSQ3jgkn30drvh6Ua9wQ-IMUB4IFnaro0LsEu4m1H-Af5tz-m6IaKJ4Wnddpa22znr-bWnvwPwJg10HhtEJwMpRZ9rLBEnCOpyOkx1FGjulgv29sXuIf94PDiegZ12L0zDD9FNuJFluP81GfhFbn8z8rPiO5p5IIaz8IALRFfkEX3tuKNo67FDW5zW_3EQ9LRCFMbTPXp7MLrjYd52WN2IM34EJ21bm0CT0-26Utv66g8ax3t25jEseE-UjRrVeQIzplyEpVGJKPz8J9tgLjbUTbovwvyeX4JfgutRXU0q-aMot5jCupjURc586m8my5w1ISJsYhlewRpupKqOSf2SFeW3Qrl4MSzi8470gmQLOjrITamUiinz1K9TRnPGKEn59urpMhyM3x-83e37bA59HVMoVchDboXUlO5aKGVNorixSnFudIL4Xkfo5-dWJxJBVpJH6JuECIa4tFoEXMdPYa6clOYZMKuMSJOY68CEXOXBMNY8yK2yUgxsHEQ92Gy_aqY90zkl3DjLWsSDrztzr7sH652o7-nfhFZb1ci8hU-zKAqJuQdxfA9ed7fRNmnBRZZmUqNMmAra2jbAJq00KtXVQv9W9DZTbKxTjH9Xn33-cOQKz_9f9BXMf3k3xtP9Ty_gITp5wyZIcxXmqsvarKEjVamXzmB-AYpJGew
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Autotaxin%2C+bile+acid+profile+and+effect+of+ileal+bile+acid+transporter+inhibition+in+primary+biliary+cholangitis+patients+with+pruritus&rft.jtitle=Liver+international&rft.au=Hegade%2C+Vinod+S&rft.au=Pechlivanis%2C+Alexandros&rft.au=McDonald%2C+Julie+A+K&rft.au=Rees%2C+Douglas&rft.date=2019-05-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=1478-3223&rft.eissn=1478-3231&rft.volume=39&rft.issue=5&rft.spage=967&rft.epage=975&rft_id=info:doi/10.1111%2Fliv.14069&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-3223&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-3223&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-3223&client=summon